增强复发性上皮性卵巢癌放疗敏感性的相关因素

doi:10.12280/gjfckx.20200534

摘要/Abstract

摘要：

卵巢癌起病隐匿,大多数患者确诊时已到中晚期。卵巢癌的一线治疗目前仍以手术为主,辅以化疗和放疗。卵巢癌复发率高,即使治疗后获得完全缓解的患者复发率可达80%。放疗可有效控制复发性上皮性卵巢癌、晚期卵巢癌及特殊部位（如盆腔壁、淋巴结等）病灶的发展,缓解症状,提高生活质量、延长无进展生存期。但是由于卵巢癌细胞对放射线的抗性,影响了放疗对卵巢癌的疗效。因此,提高卵巢癌细胞对放射线的敏感性,可提高放疗对卵巢癌的疗效。对增强复发性上皮性卵巢癌放疗敏感性的相关因素进行综述。

关键词: 卵巢肿瘤, 肿瘤复发, 局部, 放射疗法, 辐射耐受性, 药用制剂, 基因, 复发性上皮性卵巢癌

Abstract:

Ovarian cancer has an insidious onset, and most patients are diagnosed in the middle and advanced stages. The first-line treatment of ovarian cancer is still based on surgery, supplemented by chemotherapy and radiotherapy. Ovarian cancer has a high recurrence rate, with more than 80% of recurrences even after complete remission after treatment. Radiotherapy can effectively control symptoms, relieve tumor development, improve quality of life and prolong progression-free survival for recurrent epithelial ovarian cancer, advanced lesions and lesions at special sites (such as pelvic wall, lymph nodes, etc.). However, due to the resistance of ovarian cancer cells to radiation, the efficacy of radiotherapy for ovarian cancer is affected. Therefore, improving the radiosensitivity of ovarian cancer cells can improve the efficacy of radiotherapy for ovarian cancer. The aim of this study was to review the factors associated with enhanced radio sensitivity in recurrent epithelial ovarian cancer.

Key words: Ovarian neoplasms, Neoplasm recurrence, local, Radiotherapy, Radiation tolerance, Pharmaceutical preparations, Genes, Recurrent epithelial ovarian cancer

俞晓雲, 李睿彦, 何玲玲, 冯淑杰, 王海琳. 增强复发性上皮性卵巢癌放疗敏感性的相关因素[J]. 国际妇产科学杂志, 2021, 48(2): 154-158.

YU Xiao-yun, LI Rui-yan, HE Ling-ling, FENG Shu-jie, WANG Hai-lin. Factors Related to Enhanced Radiosensitivity of Recurrent Epithelial Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(2): 154-158.

参考文献 39

[1]	Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review[J]. Semin Oncol Nurs, 2019,35(2):151-156. doi: 10.1016/j.soncn.2019.02.001. pmid: 30867104
[2]	Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017,41:3-14. doi: 10.1016/j.bpobgyn.2016.08.006. pmid: 27743768
[3]	Korkmaz T, Seber S, Basaran G. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials[J]. Crit Rev Oncol Hematol, 2016,98:180-188. doi: 10.1016/j.critrevonc.2015.10.006. doi: 10.1016/j.critrevonc.2015.10.006 pmid: 26603345
[4]	卵巢癌诊疗规范（2018年版）[J]. 肿瘤综合治疗电子杂志, 2019,5(2):87-96. doi: CNKI:SUN:ZLZD.0.2019-02-017.
[5]	Chang JS, Kim SW, Kim YJ, et al. Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial[J]. Gynecol Oncol, 2018,151(1):39-45. doi: 10.1016/j.ygyno.2018.08.012. doi: 10.1016/j.ygyno.2018.08.012 pmid: 30146110
[6]	Iorio GC, Martini S, Arcadipane F, et al. The role of radiotherapy in epithelial ovarian cancer: a literature overview[J]. Med Oncol, 2019,36(7):64. doi: 10.1007/s12032-019-1287-8.
[7]	周璟, 黄学惠. 卵巢癌的治疗现状回顾[J]. 现代肿瘤医学, 2012,20(6):1308-1311. doi: 10.3969/j.issn.1672-4992.2012.06.73.
[8]	中华医学会妇科肿瘤学分会. 卵巢癌PARP抑制剂临床应用指南[J]. 现代妇产科进展, 2020,29(5):321-328. doi: 10.13283/j.cnki.xdfckjz.2020.05.001.
[9]	Jiang X, Li W, Li X, et al. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer[J]. Cancer Manag Res, 2019,11:4371-4390. doi: 10.2147/CMAR.S200524.eCollection2019. pmid: 31191001
[10]	Tuli R, Shiao SL, Nissen N, et al. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer[J]. EBioMedicine, 2019,40:375-381. doi: 10.1016/j.ebiom.2018.12.060. doi: 10.1016/j.ebiom.2018.12.060 pmid: 30635165
[11]	Wang F, Zhu S, Fisher LA, et al. Phosphatase 1 Nuclear Targeting Subunit Mediates Recruitment and Function of Poly (ADP-Ribose) Polymerase 1 in DNA Repair[J]. Cancer Res, 2019,79(10):2526-2535. doi: 10.1158/0008-5472.CAN-18-1673. doi: 10.1158/0008-5472.CAN-18-1673 pmid: 30733193
[12]	Jain PG, Patel BD. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update[J]. Eur J Med Chem, 2019,165:198-215. doi: 10.1016/j.ejmech.2019.01.024. doi: 10.1016/j.ejmech.2019.01.024 pmid: 30684797
[13]	Harrision D, Gravells P, Thompson R, et al. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly (ADP-Ribose) Polymerase (PARP)- Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy[J]. Front Mol Biosci, 2020,7:191. doi: 10.3389/fmolb.2020.00191. doi: 10.3389/fmolb.2020.00191 pmid: 33005627
[14]	Dungey FA, Löser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly (ADP-Ribose) polymerase: mechanisms and therapeutic potential[J]. Int J Radiat Oncol Biol Phys, 2008,72(4):1188-1197. doi: 10.1016/j.ijrobp.2008.07.031.
[15]	Jannetti SA, Zeglis BM, Zalutsky MR, et al. Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy[J]. Front Pharmacol, 2020,11:170. doi: 10.3389/fphar.2020.00170. pmid: 32194409
[16]	Zhao W, Hu H, Mo Q, et al. Function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells[J]. Int J Clin Exp Pathol, 2019,12(10):3915-3920. pmid: 31933782
[17]	Mathews CA, Moore KN, Colombo N, et al. Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial[J]. Clinical Oncol, 2019,37(suppl 15):5541. doi: 10.1200/JCO.2019.37.15_suppl.5541.
[18]	陈文佳, 毛霞, 张彦琼, 等. 青蒿琥酯对肿瘤放化疗增敏作用的研究现状分析和展望[J]. 中国中药杂志, 2019,44(23):5231-5239. doi: 10.19540/j.cnki.cjcmm.20190828.405.
[19]	Fei Z, Gu W, Xie R, et al. Artesunate enhances radiosensitivity of esophageal cancer cells by inhibiting the repair of DNA damage[J]. J Pharmacol Sci, 2018,138(2):131-137. doi: 10.1016/j.jphs.2018.09.011. pmid: 30337244
[20]	Luo J, Zhu W, Tang Y, et al. Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo[J]. Radiat Oncol, 2014,9:84. doi: 10.1186/1748-717X-9-84. doi: 10.1186/1748-717X-9-84 pmid: 24666614
[21]	Wang B, Hou D, Liu Q, et al. Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51[J]. Cancer Biol Ther, 2015,16(10):1548-1556. doi: 10.1080/15384047.2015.1071738.
[22]	Song Q, Jiang S, Zhang X, et al. Radiosensitivity of human ovarian cancer cells is enhanced by pseudolaric acid B due to the inhibition of the Ras/Raf/ERK signaling pathway[J]. Exp Ther Med, 2018,15(1):685-690. doi: 10.3892/etm.2017.5500. doi: 10.3892/etm.2017.5500 pmid: 29399072
[23]	Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities[J]. Oncogene, 2011,30(32):3477-3488. doi: 10.1038/onc.2011.160. doi: 10.1038/onc.2011.160 pmid: 21577205
[24]	Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer[J]. Nat Rev Cancer, 2009,9(3):167-181. doi: 10.1038/nrc2583. doi: 10.1038/nrc2583 pmid: 19238149
[25]	Ding K, Ji J, Zhang X, et al. RNA splicing factor USP39 promotes glioma progression by inducing TAZ mRNA maturation[J]. Oncogene, 2019,38(37):6414-6428. doi: 10.1038/s41388-019-0888-1. doi: 10.1038/s41388-019-0888-1 pmid: 31332287
[26]	王卓, 纪妹, 赵曌, 等. 上皮性卵巢癌中USP39的表达及其临床意义[J]. 现代妇产科进展, 2020,29(2):106-110. doi: 10.13283/j.cnki.xdfckjz.2020.02.006.
[27]	Wang L, Chen T, Li X, et al. USP39 promotes ovarian cancer malignant phenotypes and carboplatin chemoresistance[J]. Int J Oncol, 2019,55(1):277-288. doi: 10.3892/ijo.2019.4818. pmid: 31180526
[28]	颜伟, 王雅琦, 李江龙, 等. USP39沉默对卵巢癌细胞放疗敏感性的影响[J]. 实用癌症杂志, 2020,35(4):523-524,529. doi: 10.3969/j.issn.1001-5930.2020.04.001.
[29]	周玲丽, 曹骥, 李薇, 等. RNA 干扰 FABP5基因对人肝癌 HepG2细胞裸鼠移植瘤生长的影响[J]. 中国病理生理杂志, 2015,31(4):603-608. doi: 10.3969/j.issn.1000-4718.2015.04.005.
[30]	Kawaguchi K, Senga S, Kubota C, et al. High expression of Fatty Acid-Binding Protein 5 promotes cell growth and metastatic potential of colorectal cancer cells[J]. FEBS Open Bio, 2016,6(3):190-199. doi: 10.1002/2211-5463.12031. pmid: 27047747
[31]	Ogawa R, Ishiguro H, Kuwabara Y, et al. Identification of candidate genes involved in the radiosensitivity of esophageal cancer cells by microarray analysis[J]. Dis Esophagus, 2008,21(4):288-297. doi: 10.1111/j.1442-2050.2007.00759. pmid: 18477249
[32]	钱林华. 双向调控FABP-5表达对人卵巢癌SKOV3细胞裸鼠移植瘤放射敏感性的影响[J]. 中国老年学杂志, 2019,39(24):6093-6097. doi: 10.3969/j.issn.1005-9202.2019.24.060.
[33]	张金玉, 乔树, 陈保平. Rsf-1在几种常见恶性肿瘤中的表达及意义[J]. 医学研究与教育, 2018,35(5):12-18. doi: 10.3969/j.issn.1674-490X.2018.05.003.
[34]	王翔宇, 许晋铨, 孙丽, 等. Rsf-1/HBXAP基因在宫颈癌中的表达及临床病理意义[J]. 现代妇产科进展, 2017,26(2):104-108. doi: 10.13283/j.cnki.xdfckjz.2017.02.006.
[35]	Sheu JJ, Guan B, Choi JH, et al. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability[J]. J Biol Chem, 2010,285(49):38260-38269. doi: 10.1074/jbc.M110.138735. doi: 10.1074/jbc.M110.138735 pmid: 20923775
[36]	Sheu JJ, Choi JH, Yildiz I, et al. The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1[J]. Cancer Res, 2008,68(11):4050-4057. doi: 10.1158/0008-5472.CAN-07-3240. doi: 10.1158/0008-5472.CAN-07-3240 pmid: 18519663
[37]	Wang X, Sheu JJ, Lai MT, et al. RSF-1 overexpression determines cancer progression and drug resistance in cervical cancer[J]. Biomedicine (Taipei), 2018,8(1):4. doi: 10.1051/bmdcn/2018080104.
[38]	谢兆光, 王翔宇, 饶林丽, 等. RNA干扰染色体空间重组因子1对宫颈腺癌放化疗敏感性的影响[J]. 肿瘤药学, 2019,09(1):20-25. doi: 10.3969/j.issn.2095-1264.2019.01.05.
[39]	Tian J, Kong E, Wang X, et al. RSF-1 siRNA Enhances Tumor Radiosensitivity in Cervical Cancer via Enhanced DNA Damage, Cell Cycle Redistribution, and Promotion of Apoptosis[J]. Onco Targets Ther, 2020,13:3061-3071. doi: 10.2147/OTT.S246632. doi: 10.2147/OTT.S246632 pmid: 32308437